Status:
COMPLETED
Study of Home Full Blood Count (FBC) Telemonitoring Device for Chemotherapy Patient
Lead Sponsor:
Philips Healthcare
Collaborating Sponsors:
The Royal Marsden Hospital
Conditions:
Cancer
Eligibility:
All Genders
19-75 years
Phase:
NA
Brief Summary
The Zodiac, a Philips healthcare telemonitoring system has been devised to allow cancer patients receiving chemotherapy to test their blood count at home. It is anticipated that the system will allow ...
Detailed Description
Philips Healthcare has devised a new home full blood count (FBC) home telemonitoring system which will allow cancer patients receiving chemotherapy to test their blood count at home (haemoglobin, haem...
Eligibility Criteria
Inclusion
- Male or female, age \> 18.
- Able to give informed written consent in the English language.
- Diagnosis of cancer and receiving chemotherapy or with a planned chemotherapy start date within 2 weeks of enrolment.
- Patients who are able to perform finger prick test to obtain capillary blood.
Exclusion
- Inability to give informed consent due to mental capacity or language problems.
- Patients at risk of bruising or bleeding as a result of their disease or treatment.
- Patients at risk of bruising or bleeding due to anticoagulants (heparin or warfarin), aspirin or thrombocytopenia (platelet count \<80).
- Patients with diabetes mellitus
- Patients with peripheral neuropathy
Key Trial Info
Start Date :
June 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2012
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01436669
Start Date
June 1 2011
End Date
May 1 2012
Last Update
March 18 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Marsden Hospital
Belmont, Surrey, United Kingdom